On a mission to combat hereditary cancer, EVITA is currently aiming to join forces with other European partners who may be interested in developing a groundbreaking project under the Horizon Europe Framework Programme. EVITA’s attention is specifically drawn to the call “Accessible and affordable tests to advance early detection of heritable cancers in European regions (HORIZON-MISS-2024-CANCER-01-03).”
In this context, it is also relevant to share that the EVITA Platform, successfully launched on February 22, 2024, and currently available in Portuguese, stands as a testament to EVITA’s commitment to early detection and prevention. This digital tool has already contributed significantly to increase awareness and facilitate the detection of hereditary cancer mutation carriers.
By granting citizens access to a comprehensive risk assessment questionnaire, the platform serves as a vital tool to identify genetic predispositions to hereditary cancer early on. The questionnaire, in which users are asked about their family’s and personal history of cancer, offers immediate feedback, signaling whether there seems to be an elevated risk of hereditary cancer within the user’s family or not.
In under two weeks, the platform attracted 1000 registered users, indicative of significant public interest. Currently, the user base has grown to nearly 2000 individuals, with 81% of them receiving an “elevated risk” result upon answering the questionnaire. Furthermore, nearly 800 registered platform users have provided their minimum demographic data, enabling further studies of the cohort.This notable interest highlights the platform’s relevance and effectiveness in empowering individuals to proactively manage their hereditary cancer risk.
Moreover, EVITA Platform will soon be available in english, making it an invaluable resource for individuals with an heightened risk for hereditary cancer across Europe as well as an important tool that could facilitate research activities developed within the scope of an european project such as the one proposed by the HORIZON-MISS-2024-CANCER-01-03 call.
In light of this initiative, EVITA is actively seeking partners to collaborate on research projects and advance early detection of hereditary cancers all across Europe. Interested parties are encouraged to contact EVITA via email at mariana.coutinho@evitacancro.org to explore potential collaborations.
If you’re ready to be at the forefront of innovation in cancer prevention, now is the time to join EVITA on its journey. Together, we can turn the tide against hereditary cancers and pave the way towards a future where early detection is not just a possibility but a reality for all. Contact EVITA today to learn more about partnership opportunities and become a catalyst for change in the fight against cancer.
Stay tuned for more updates from EVITA as we embark on this transformative journey towards a future where early detection saves lives and paves the way for a healthier tomorrow.
Discover more about Evita Cancro:
EVITA is a portuguese non-profit patient organisation, that, since 2011, is on a mission to save lives and improve the quality-of-life of oncology patients and individuals as well as families affected by hereditary cancer. EVITA’s president, Tamara Milagre, is a certified Patient Expert by the European Patients Academy (EUPATI), a member of the ePAG Council at the European Reference Network GENTURIS and an active member of National Cancer Hub Portugal. She passionately advocates for the prevention and treatment of sporadic and hereditary cancers and supports people who deal with the risk factors associated with these diseases. Tamara Milagre has been distinguished by the Portuguese Minister of Research and Education and received the Medal of Scientific Merit 2020.
